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Abstract As a new anticancer treatment option, vaccinia
virus (VACV) has shown remarkable antitumor activities
(oncolysis) in preclinical studies, but potential infection of
other organs remains a safety concern. We present here
genome comparisons between the de novo sequence of GLV-
1h68, a recombinant VACV, and other VACVs. The identi-
Wed diVerences in open reading frames (ORFs) include genes
encoding host-range selection, virulence and immune modu-
lation proteins, e.g., ankyrin-like proteins, serine proteinase
inhibitor SPI-2/CrmA, tumor necrosis factor (TNF) receptor
homolog CrmC, semaphorin-like and interleukin-1 receptor
homolog proteins. Phylogenetic analyses indicate that GLV-
1h68 is closest to Lister strains but has lost several ORFs
present in its parental LIVP strain, including genes encoding
CrmE and a viral Golgi anti-apoptotic protein, v-GAAP. The
reduced pathogenicity of GLV-1h68 is conWrmed in male
mice bearing C6 rat glioma and in immunocompetent mice
bearing B16-F10 murine melanoma. The contribution of for-
eign gene expression cassettes in the F14.5L, J2R and A56R
loci is analyzed, in particular the contribution of F14.5L inac-
tivation to the reduced virulence is demonstrated by compar-
ing the virulence of GLV-1h68 with its F14.5L-null and
revertant viruses. GLV-1h68 is a promising engineered
VACV variant for anticancer therapy with tumor-speciWc
replication, reduced pathogenicity and benign tissue tropism.
Keywords Virulence · Immune modulation · Tissue 
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ACAM2000 (AY313847)
DUKE Vaccinia virus strain DUKE (DQ439815)
MVA Vaccinia virus strain Ankara (U94848)
MP_ZAI Monkeypox virus strain 
Zaire-96-I-16 (AF380138)
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CAM_CMS Camelpox virus CMS (AY009089)
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Introduction
Vaccinia virus (VACV) is the prototype virus of the ortho-
poxvirus genus in the poxvirus family. It has a linear,
approximately 190-kb, double-stranded DNA genome,
encoding more than 200 ORFs. VACV strains have been
used extensively as vaccines and have played a central role
in the eradication of the smallpox disease. More recently,
research has focused on the potential of using VACV as an
oncolytic virus for therapy of tumors. Many features associ-
ated with VACV are considered valuable for viral therapy,
including the large cloning capacity, the natural tumor colo-
nization capability, a short life cycle with strong lytic abil-
ity, and the capability to infect and replicate in human cells
without causing natural disease in humans (Shen and Nem-
unaitis 2005). Several VACV vectors have shown remark-
able antitumor and antimetastases results in preclinical
studies; however, the signiWcant level of infection in other
organs remains a safety concern for systemic administra-
tion (Thorne et al. 2005). Our oncolytic VACV GLV-1h68
may be a potential improvement. To this end, its attenuation
basis is studied here Wrst by triple genome comparison, overall
tissue tropism and key eVects of engineered mutations.
VACV strains exhibit variations in virulence, as well as
variations in host and tissue speciWcity or tissue tropism.
Sequence analysis of VACV genomes has improved our
understanding of the potential functions of viral gene prod-
ucts and host–virus interactions (Goebel et al. 1990; Anto-
ine et al. 1998; Upton et al. 2003; Li et al. 2006). It is also
known that several nonessential genes, such as J2R (thymi-
dine kinase TK) (Buller et al. 1985), C11R (secreted epider-
mal growth factor-like) (Buller et al. 1988),  A56R
(hemagglutinin HA) (Shida et al. 1988), and B8R (soluble
interferon-gamma receptor-like) (Verardi et al. 2001) result
in reduced virulence when deleted or disrupted experimentally.
LIVP is a VACV vaccine strain originated from the
Lister strain, which was adapted to calf skin in the Institute
of Viral Preparations, Moscow, Russia (Al’tshtein et al.
1985). Western Reserve (WR) is derived from the New
York City Board of Health (NYCBH) strain by repeated
passages in the mouse brain (Henderson and Moss 1999).
In a previous study, we reported that rVV-ruc-gfp, a recom-
binant LIVP carrying a fusion gene encoding light-emitting
proteins, enters, replicates in, and reveals the locations of
tumors in mice (Yu et al. 2004). Subsequently, a new
recombinant virus, GLV-1h68, was constructed by insert-
ing three expression cassettes into the F14.5L, J2R, and
A56R loci of the viral genome (Zhang et al. 2007). When
administered intravenously, GLV-1h68 demonstrated
remarkable tumor targeting and a much improved safety
proWle, as compared to its parental LIVP strains and the
WR strains. In female nude mice bearing human GI-101A
breast tumor xenografts that were injected with wt-WR or
TK¡ WR, a signiWcantly elevated viral distribution was
found in all organs examined, particularly in brain and
ovarian tissues. In contrast, both the brain and ovaries were
free of virus particles in mice injected with GLV-1h68.
To help understand the diVerences in the biodistribution
between the LIVP and WR strains and the factors contrib-
uted to reduced virulence of GLV-1h68, we sequenced the
genomic DNAs of wt-LIVP and GLV-1h68. We present
here extensive genome comparisons between GLV-1h68,
Lister, WR and Copenhagen (COP), based on the de novo
sequence of GLV-1h68 and the functional analysis of indi-
vidual ORFs. Since the LIVP strains exhibited signiWcantly
diVerent tissue colonization patterns, as well as remarkably
host-range restrictions compared to the neurovirulent WR
strains (Zhang et al. 2007), we focus our analyses on genes
suggested to be involved in tissue tropism, host-range
restriction and immune modulation. A number of gene
diVerences identiWed in these genomes support our obser-
vation of viral attenuation in GLV-1h68. The reduced path-
ogenicity of GLV-1h68, while remaining replication
competent in tumors, was further conWrmed in more tumor
models, and the contribution of inactivated F14.5L to the
attenuation of GLV-1h68 was investigated by comparing
the virulence of GLV-1h68 with its F14.5L-null and revert-
ant viruses.
Materials and methods
Cells and virus strains
CV-1 African green monkey kidney Wbroblast, C6 rat gli-
oma, and B16-F10 murine melanoma cells were purchased
from the American Type Culture Collection (ATCC,
Manassas, VA). These cells were cultured in Dulbecco’s
modiWed Eagle’s medium (DMEM), supplemented with
antibiotic–antimycotic solution (penicillin G 100 U ml¡1,Mol Genet Genomics (2009) 282:417–435 419
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amphotericin B 250 ng ml¡1, streptomycin 100 U ml¡1)
and 10% fetal bovine serum (FBS) at 37°C under 5% CO2.
Mouse embryonic Wbroblasts MEF (CF-1) were originally
obtained from ATCC and cultured in DMEM with 15%
FBS. The construction of recombinant VACV GLV-1h68
has been described previously (Zhang et al. 2007). BrieXy,
a Renilla luciferase-Aequorea green Xuorescent protein
(RUC-GFP) fusion cDNA under the control of the vaccinia
synthetic early/late promoter was inserted into the F14.5L
locus of wt-LIVP. One green plaque was clonally puriWed
and designated as the single-mutant virus GLV-1d27. Then,
a -galactosidase (lacZ) encoding cDNA, under the control
of p7.5 promoter, was inserted into the TK locus of GLV-
1d27 to generate the double-mutant virus GLV-1f65, and a
-glucuronidase (gusA) encoding cDNA under the control
of p11 promoter was inserted into the HA locus of GLV-
1f65 to generate the triple-mutant virus GLV-1h68. All the
recombinant viruses were puriWed through several rounds
of plaque puriWcation. Other strains included for compari-
son were WR wt and WR TK¡ strain GLV-0b05, in which
the TK locus was disrupted by the insertion of RUC-GFP
and  lacZ expression cassettes, as described previously
(Zhang et al. 2007). The WR viruses were chosen because
WR is the most extensively studied laboratory strain, and
its wt genome sequence is readily available for comparative
analysis.
PuriWcation of viral DNA for sequencing
Both GLV-1h68 and wt-LIVP were propagated and titrated
in CV-1 cell monolayers. CV-1 cells infected with GLV-
1h68 or wt-LIVP were harvested by centrifugation and dis-
rupted by three cycles of freeze and thaw. Cell debris and
nuclei were removed from cell lysates by low-speed centri-
fugation. The recovered viral particles were then puriWed
by centrifugation through sucrose cushions and sucrose
gradients (20–40%) using established protocols (Joklik
1962). Genomic viral DNA was extracted from puriWed
virions after treatment with proteinase K and followed
by phenol–chloroform extraction, as described previously
(Earl et al. 1998). The puriWed GLV-1h68 and wt-LIVP
DNAs were used for sequencing by AGOWA GmbH
(Germany).
Sequence analysis of GLV-1h68
The genomic DNA prepared from puriWed GLV-1h68 was
sequenced by a shotgun approach and assembled by
AGOWA GmbH. The pUC19 hybrid plasmids were
sequenced to an 8 £ coverage, and only high quality reads
(PHRED quality score: 20) were put into the assembly. Gap
closure was performed by additional sequencing runs on
the shotgun clones or by PCR using the viral genomic
DNA. Because the terminal hairpin loops were not
sequenced, the leftmost nucleotide of the assembled
sequences was arbitrarily designated as base number 1.
ORFs were predicted using multiple sequence analysis
tools, including ORF Finder (http://www.ncbi.nih.gov/gorf/
gorf.html), GeneMark (Besemer and Borodovsky 2005)
and Glimmer3 (Delcher et al. 2007), to enhance sensitivity
and accuracy. ORFs that were predicted to be shorter than
50 amino acids were analyzed with BLAST further on other
known virus genomes and recorded only when at least one
highly identical hit with low E-value (below 10¡6) was
present.
The recombination regions in GLV-1h68, including
F14.5L, J2R, A56R, were Wrst replaced by the consensus
sequence of corresponding regions of wt-LIVP. Afterward,
the sequence was compared with the sequence of the WR
strain using Smith–Waterman algorithm (Smith and Water-
man 1981) on a Genematcher2 system. Bioperl modules
(Stajich et al. 2002) were used to parse the reports automat-
ically. The inGeno software was applied to analyze the
rearrangement events (Liang and Dandekar 2006). The
same comparison procedures described above were
repeated on various poxvirus genomes. In addition to WR,
we examined COP, MVA and Tiantan strains, and then the
cowpox, camelpox, monkeypox and variola viruses. Subse-
quently, the annotation was improved and conWrmed with
Prosite (Sigrist et al. 2002) and PFAM/HMMER search
(Bateman et al. 2004). The detailed motif hits are available
in the supplementary list S1 (online at http://vaccinia.bio-
apps.biozentrum.uni-wuerzburg.de. The sequence data of
GLV-1h68 has been submitted to NCBI database under
GenBank accession no. EU410304).
Phylogenetic analysis
Phylogenetic analysis of GLV-1h68 was carried out on a
conserved 82-kb nucleotide sequence, which is present in
the central conserved region of 16 orthopoxvirus genomes
(suppl. list S2). Corresponding regions were located from
dot plots using the Dotter software (Sonnhammer and
Durbin  1995) and aligned using MAFFT (Katoh et al.
2005). ClustalW was used to construct a Neighbor-Join-
ing tree (Thompson et al. 1994), and its robustness was
detected using bootstrap methods. NJPlot (Perrière and
Gouy  1996) and SplitsTree4 (Huson and Bryant 2006)
were used to analyze and plot the phylogenetic tree with
bootstrapping.
Detection of crmE gene by PCR
The genomic DNAs from wt-LIVP, GLV-1d27, and GLV-
1h68 were used as the templates for PCR ampliWcation of
the speciWc crmE gene fragment. The primer sequences for420 Mol Genet Genomics (2009) 282:417–435
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crmE were 5-GTCCGAGTGACACATTCACG-3 and
5-ACCCACGACCACATTTTGTT-3, which correspond
to the crmE gene (mO259R) 181,487–181,506 and
181,677–181,696, respectively, in Lister isolate LC16mO
(Genbank accession no. AY678277). The primer sequences
for the conserved F13L gene fragment, which served as the
positive control, were 5-CGCGTCATTTACTGGAGGAT-3
and 5-GCAGTGCTAACTGGCAAACA-3, which corre-
spond to 40,770–40,789 and 40,613–40,632, respectively,
in the GLV-1h68 genome sequence, or 44,171–44,190 and
44,014–44,033, respectively, in the LC16mO genome
sequence.
Sequencing of the right terminal fragment of wt-LIVP
The genomic DNAs from wt-LIVP and GLV-1h68 were
used as the templates for PCR with the primer 5-GCT
ATGATTAACTCCCACGATACTATGC-3, which corre-
sponds to nucleotides 178,812–178,839 (mO257L) in
LC16mO or 188,293–188,320 (GL272) in GLV-1h68, and
the primer 5-CCTTACGACGTTTACATCGACGAG-3,
which corresponds to 184,655–185,678 (mORTR02R) in
LC16mO or 199,241–199,264 (GL285) in GLV-1h68. The
PCR products were checked on 1% agarose gel, and the
major PCR product for wt-LIVP was cloned into pCR-
Blunt II-TOPO vector (Invitrogen), and one of the clones
was sequenced by primer-walking. This sequence was com-
pared with the corresponding gene segments from GLV-
1h68, WR and other Lister strains.
Construction of the F14.5L-revertant virus
To make the F14.5L-revertant virus (i.e. GLV-1e135), the
RUC-GFP expression cassette in GLV-1h68 was removed
and the F14.5L locus was restored to its wild-type
sequence. The wild-type sequence spanning the F14.5L
region (including F14.5L and its Xanking region, approxi-
mately 1.1 kb in length) of the wt LIVP genome was PCR
ampliWed with primers 5-ACTAGT (SpeI) TTCCCTCGT
TCATCTAGCAAAAC-3 and 5-AAGCTT (HindIII)
TGAGGAGTATTGCGGGGCTA-3. The PCR product
was cloned into pCR-Blunt II-TOPO vector (Invitrogen)
and the sequence of wt F14.5L was conWrmed. The wt
F14.5L was released by HindIII and SpeI, then subcloned
into the pCR2.1 vector (Invitrogen) with the same cuts, in
which a xanthine-guanine phosphoribosyltransferase (gpt)
expression cassette, PCR ampliWed from pUCP7.5-gpt-1
(kindly provided by Dr. Kangla Tsung, University of Cali-
fornia, San Francisco, USA), was inserted in the EcoRI site.
The Wnal construct pCR-wtF14.5L-gpt1 was conWrmed by
sequencing. This construct was used to make the recombi-
nant virus GLV-1e135 from the parental virus, GLV-1h68,
using the methods described by Falkner and Moss (1990).
Construction of the F14.5L-null virus
To generate a F14.5L-null virus, the RUC-GFP expression
cassette in the F14.5L locus of GLV-1h68 was replaced by
a short nonsense sequence, so that the F14.5L would
remain inactivated. This F14.5L-null virus, named GLV-
1h71, was engineered as follows. The left and right Xanking
sequences of F14.5L were PCR-ampliWed from wt LIVP
using the primers 5-GCGCATATGTAGAAGAATTGAT
AAATATG-3 and 5-GCCGCAGGATCCTGCGAAG
CTTACAGACACGAATATGACTAAACCGATG-3 (left
Xank), 5-GTCTGTAAGCTTCGCAGGATCCTGCGGCC
GCCATCGTCGGTGTGTTGTC-3 and 5-GCGGAATT
CAGAGGATTACAACAAAAAGATG-3 (right Xank). The
two fragments were joined together using the method of
gene-splicing by overlapping extension (Horton et al. 1993).
The resulting fragment was digested with NdeI and EcoRI,
and then cloned into the same-cut pUCP7.5-gpt-1 to yield
pNCVVf14.5lT. The recombinant virus GLV-1h71 was
generated using pNCVVf14.5lT from the parental virus
GLV-1h68.
Viral replication in cell cultures
CV-1 (1 £ 105), C6 (2 £ 105), and B16-F10 (2 £ 105) cells
were seeded onto 24-well plates, and MEF (CF-1)
(1.1 £ 105) cells were seeded onto 12-well plates. After 24 h
in culture, the cells were infected with individual viruses at a
multiplicity of infection (MOI) of 0.001 (for CV-1 or C6
cells) or an MOI of 0.01 (for MEF or B16-F10 cells). The
cells were incubated at 37°C for 1 h with brief agitation
every 10 min to allow infection to occur. The infection
medium was removed and the cells were incubated in fresh
growth medium until harvested at 24, 48, or 72 h after infec-
tion. Viral particles from the infected cells were released by
a quick freeze-thaw cycle, and the titers determined as
medium (pfu ml¡1; plaque forming units per milliliter) in
duplicate by plaque assay in CV-1 cell monolayers.
To investigate whether an inactivated F14.5L aVects the
viral infection and replication in CV-1 cells, CV-1 cells
seeded at 5 £ 105 cells/well were infected with GLV-1h68,
GLV-1h71 or GLV-1e135 at an MOI of 0.01 and harvested
at 24, 48 and 72 h after infection. The infection was per-
formed in triplicate for each virus. Viral particles from
infected cells were released and titrated as above, and the
titers were determined as pfu/106 cells.
Viral distribution and pathogenicity studies
All mice were cared for and maintained in accordance with
animal welfare regulations under an approved protocol by
the Institutional Animal Care and Use Committee of
LAB Research International Inc. and Explora BiolabsMol Genet Genomics (2009) 282:417–435 421
123
(San Diego, CA, USA). Mice with C6 xenograft tumors
were developed by implanting C6 cells (5 £ 105 cells in
100 l of PBS) subcutaneously into the right hind leg of
6- to 8-week-old male nude mice (NCI:Hsd:Athymic
Nude-Foxn1nu, Harlan). To compare the biodistribution and
pathogenicity of individual virus strains, on day 7 after C6 cell
implantation, when the median tumor volume was approxi-
mately 150 mm3, a single dose of virus (1 £ 107 pfu in
100 l PBS) was injected via the tail vein (n = 4 per virus).
Body weight was monitored, and mice were checked daily
for any sign of toxicity. Mice were sacriWced 14 days after
virus injection, and the tumors and organs were analyzed
for viral titers.
Similarly, the tissue distribution of viral particles and
the pathogenicity of the viruses were also assessed in a
syngeneic murine melanoma model. B16-F10 cells
(2 £ 105 cells) in 40 l of PBS were injected into the foot
pad of 6- to 8-week-old immunocompetent male C57BL/6
mice (Harlan). On day 18 after cell implantation, when the
median tumor volume reached approximately 100 mm3, a
single dose of virus (1 £ 107 pfu in 100 l PBS) was
injected intravenously (n = 4 per virus). Mice were sacri-
Wced 10 days after virus injection, and the tissue distribu-
tion of virus was analyzed.
To investigate whether a restored wt F14.5L increased
virulence in vivo, female nude mice (4–5 weeks old; Har-
lan; n = 8 for PBS, GLV-1h68 or GLV-1h71 treated group,
and n = 7 for the GLV-1e135 group) were administrated an
intranasal application of 2 £ 106 pfu/20 l of individual
virus per mouse. The mice were monitored twice weekly
for body weight, and the survival rate was recorded for
each treatment group during a period of 10 weeks.
Statistical analysis
Statistical analyses were performed with SPSS, version 11
(SPSS Inc., Chicago, IL, USA). Comparisons of treatment
groups were made by analysis of variance (ANOVA), and
the diVerences between the groups were analyzed with an
LSD test when the ANOVA showed an overall signiW-
cance. The survival rates for the diVerent treatment groups
were compared with the Log Rank test. Values of p less
than 0.05 were considered signiWcant.
Results
Phylogenetic analysis
GLV-1h68 as a new virus with therapeutic potential was
sequenced and then compared to other VACVs. We consid-
ered (see “Discussion”) in particular the well known WR
strain and the COP strain. Further phylogenetic analysis
indicated that two Lister strains (Lister and LC16mO) were
highly similar to GLV-1h68, and that all three strains had a
recent common ancestor (Fig. 1). GLV-1h68 seemed to be
closer to WR than to COP, which was also supported by
sequence comparison results that indicated that GLV-1h68
shared more orthologous ORFs with WR than with COP
(suppl. Fig. S1). Together with other VACV strains, such as
ACAM, DUKE and MVA, these strains form a vaccinia
cluster. The closest neighbors to the vaccinia cluster were
cowpox virus (CP_GRI) and two monkeypox strains
(MP_SL and MP_ZAI), followed by the camelpox strain
(CAM_CMS). The three variola strains and the ectromelia
virus strain (ECT_MOS) were relatively distinct in the gen-
erated tree.
Genomic features of GLV-1h68
The complete sequence of GLV-1h68 allowed bioinformatic
analysis of all genes and genomic features detected. GLV-
1h68 was generated through three steps of construction as
described previously. The resulting virus contained three
foreign insertions of 1,958 bp, 8,606 bp, and 2,326 bp in the
F14.5L, J2R, and A56R loci, respectively. With these three
insertions, the size of the engineered GLV-1h68 virus was
found to be 203,057 bp with 65.78% A + T content. Without
the insertions, the viral genome was found to be comprised
of 190,167 bp with 66.57% A + T content, and can be trans-
lated into 238 “major” ORFs (not embedded ORFs, see
below). Most of the ORFs encoded protein products larger
than 50 amino acids and were non-overlapping. Only a few
weakly overlapped with other ORFs. In addition, 13 short
ORFs were included as “major” ORFs since they are present
in annotated ORFs of WR or COP. We also found 61
“minor” ORFs embedded in larger ORFs within the
genome. In total, 299 potential ORFs, listed consecutively
from left to right as they appeared in the genome, are sum-
marized in suppl. Table S1 and S2. The homologs present in
the WR genome are also listed for comparison, and the
nomenclature for the COP genome is used as reference. The
lengths, annotations and descriptions of some extremely
short ORFs are listed in suppl. Table S3. The most striking
diVerences among the ORFs of the three VACV strains are
presented in suppl. Table S4. The numbers of vaccinia major
and minor ORFs are summarized in suppl. Table S5.
Based on the annotation, we classiWed the major ORFs into
six functional categories. Figure 2 shows their distribution in
the viral genome. Sixty-one ORFs were likely to be involved
in host interactions and immune modulation, and most of
these were found to be positioned in the left and right terminal
regions and the edges of the central conserved region. Forty-
nine ORFs encoding proteins involved in viral structure and
assembly were located in the central conserved region, includ-
ing viral core proteins, plaque forming, and EEV and IEV422 Mol Genet Genomics (2009) 282:417–435
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membrane proteins (pink). Genes involved in metabolism (41
ORFs, orange) and genes involved in DNA replication, RNA
transcription and modiWcations (28 ORFs, green) were also
located in the central conserved region. The functions of 58
ORFs remained uncertain or unidentiWed (marked with clear
arrows). GL068 (F14.5L) was split into two parts by the
RUC-GFP expression cassette (marked in gray, Fig. 2). Other
foreign insertions included lacZ in the TK locus, and gusA in
the HA locus.
The sequence data for the wt-LIVP showed sub-strains
and heterogeneity at the termini. There was a central con-
served genomic region (from GL016 to GL276). It showed
an unambiguous single nucleotide substitution (a GAA
codon was changed into TAA as compared to the sequence
in WR or COP) in the middle of the J2R gene that created a
premature stop codon. We further performed an in vitro
assay (Mackett et al. 1982) which also demonstrated that
the LIVP strain indeed had a TK negative phenotype for its
wild type population (data not shown).
Comparison of ORFs involved in host-range selection 
and immune modulation
The majority of the diVerences in ORFs among the GLV-
1h68, WR and COP strains can be attributed to the ORFs
encoding ankyrin-like proteins (Table 1). Table 1 presents
additionally a variety of viral encoded complement, cyto-
kine and chemokine inhibitors, and caspase inhibitors.
Most of these immunomodulators were very well con-
served among three VACV strains, usually with over 99%
identity in the amino acid sequences. However, we found
several genes that were diVerent in GLV-1h68 than in WR.
GLV-1h68 had an intact A39R, encoding a semaphorin-like
protein, whereas, in WR, this protein was not expressed due
to the presence of a frame-shift mutation. In addition, the
TNF-receptor-like protein (vTNFR) encoded by A53R gene
seemed to be intact in GLV-1h68, but was fragmented in
WR. On the other hand, SPI-2/CrmA, which inhibits Fas-
mediated apoptosis, was intact in WR (WR195) but frag-
mented in GLV-1h68. It is also interesting to note that
GLV-1h68 had two copies of genes encoding for serine
protease inhibitor (SPI-1) and interleukin-18-binding pro-
tein, whereas in WR only one copy of each was present.
GLV-1h68 is a unique isolate from LIVP
SpeciWc genomic features point to GLV-1h68 being a
unique isolate from LIVP. Thus VACV strains USSR,
Lister, and Evans produce an additional soluble vTNFR,
named CrmE. To our surprise, however, we could not
Fig. 1 Phylogenetic tree con-
structed from orthopoxvirus 
genomes. The unrooted tree was 
generated by neighbour-joining, 
comparing highly conserved 
82 kb nucleotide sequence 
among 16 OPV genomes. Boot-
strapping values (percentage; 
1,000 trials) are shown beside 
the nodes. Please see the list of 
abbreviations and accession 
numbers for virus identiWcationMol Genet Genomics (2009) 282:417–435 423
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identify a crmE-like sequence in the genome of GLV-1h68.
To conWrm this Wnding, the genomic DNAs from wt-LIVP,
GLV-1d27, and GLV-1h68 viruses were used as the tem-
plates for PCR ampliWcation of the speciWc crmE gene frag-
ment. The PCR results indicated that wt-LIVP was crmE
positive, but that GLV-1d27 and GLV-1h68 were not
(Fig. 3a).
This unexpected Wnding regarding the loss of the crmE
gene led us to further analyze the diVerences between
GLV-1h68, wt-LIVP and other Lister strains. The genomic
DNAs from GLV-1h68 and wt-LIVP were used as the tem-
plates for PCR with primers corresponding to GL272 and
GL285 in GLV-1h68 or mO257L and mORTR02R in
LC16mO, respectively. As predicted, the PCR product for
GLV-1h68 was 10,971 bps (Fig. 3b), which was also the
size of the PCR product from its parental virus GLV-1d27
or GLV-1f65 (data not shown). The PCR product for
wt-LIVP, however, was much smaller, close to the size
predicted for LC16mO (5,866 bps) (Fig. 3b).
The sequence of the major PCR product from wt-LIVP
was analyzed and compared with the corresponding regions
from GLV-1h68, WR, and other Lister strains (e.g.
LC16mO) (Fig. 4). In addition to the missing crmE gene
(ORF  mO259R),  mO260R, mO261R, mO262L and
mORTR01R (present in the Lister strain LC16mO and wt-
LIVP) were also missing in GLV-1h68. mO261R encodes
a newly identiWed anti-apoptotic protein that is located
in the Golgi, so-called viral Golgi anti-apoptotic protein
(v-GAAP).
GLV-1h68 carries genes of WR-like origin
In contrast to the missing Lister genes, GL274 (encoding
IFN-/-receptor-like secreted glycoprotein) and GL275
(encoding ankyrin-like protein) were found in the GLV-
1h68 genome, with orthologs present in both WR and
COP. These ORFs were absent from wt-LIVP, and all
other Lister strains or derivatives sequenced (AY678275,
Fig. 2 GLV-1h68 genome map. Predicted ORFs and their lengths are
represented by colored arrows. Sixty-one ORFs involved in host inter-
actions and immune modulation are shown in blue. Located mostly in
the central conserved region are genes involved in: viral structure and
assembly (49 ORFs, shown in pink), metabolism (41 ORFs, shown in
orange) and DNA replication, RNA transcription and modiWcations
(28 ORFs, in green). The functions of 58 ORFs remain uncertain
(marked with clear arrows). The three foreign insertions are marked in
dark grey. The genome size is indicated on the right (nucleotides)424 Mol Genet Genomics (2009) 282:417–435
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AY678276, AY678277, DQ121394). Moreover, the neigh-
boring ORF upstream of crmE in the Lister strain, mO258R
(413aa), was extended into GL273 (574aa) in GLV-1h68,
suggesting an island of sequence insertion within and fol-
lowing this ORF. Considering the length diVerences of the
inverted terminal repeat (ITR) between GLV-1h68 and
other Lister strains, we decided to analyze the ORFs that
were absent from the right terminus of the Lister strains,
i.e.,  GL277-283. The comparison results indicated that
these ORFs were copies from the left terminus, including
mO008R which were fragmented into GL013/279 and
GL014/278 (Fig. 4). This additional copy of nucleotide
sequence largely extended the ITR size in GLV-1h68 in
comparison to its parental LIVP or Lister strain.
Viral replication in diVerent cell lines
In our previous studies (Zhang et al. 2007), GLV-1h68 was
evaluated in human breast tumor cell line GI-101A to
examine whether insertions in the F14.5L, J2R or A56R
locus aVected its activity. In this study, complementary to
the broad comparison of genomic and pathogenomic
features just detailed, infection studies were carried out in
further tumor cell lines to compare the infectivity and repli-
cation of individual recombinant viruses (Fig. 5b). In CV-1
Table 1 Major ORFs involved in host-range selection and immune modulation
a Denotes the corresponding ORF regions present in both WR and COP strains, with locations listed in the suppl. Table S3
b Frame-shift mutation
–, No ortholog present
Fig. 3 The PCR results indicate that the parental strain of GLV-1h68 was
a unique isolate from LIVP. a The genomic DNAs from wt-LIVP, GLV-
1d27, and GLV-1h68 viruses were used as the templates for PCR ampliW-
cation of the speciWc crmE gene fragment and the conserved F13L gene
fragment. The PCR results show that, while wt-LIVP population was crmE
positive, GLV-1d27 and GLV-1h68 were not; b The genomic DNAs from
wt-LIVP and GLV-1h68 were used as the templates for PCR with primers
corresponding to mO257L and mORTR02R in LC16mO or GL272 and
GL285 in GLV-1h68, respectively. The PCR product for GLV-1h68 was
10,971 bps as predicted. The major PCR product for wt-LIVP was much
smaller, similar to the size predicted for LC16mO (5,866 bps). This further
conWrms that GLV-1h68 was derived from a unique isolate of LIVPMol Genet Genomics (2009) 282:417–435 425
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cells all recombinant viruses replicated very well, and
showed comparable yield, similar to wt-WR and wt-LIVP
viruses. In C6 glioma cells, however, the recombinant
viruses, and particularly GLV-1h68, showed a reduced rep-
lication of up to 102-fold, compared to wt-LIVP (Fig. 5b).
Cells of mouse origins required a higher MOI for detectable
infection, which was true for both primary MEFs and the
tumor cell line B16-F10. At an MOI of 0.01, the wt-LIVP
replicated fairly well in MEFs, but the three recombinant
LIVP viruses did not replicate. In B16-F10 melanoma
cells, all viruses showed limited infection and replication
(Fig. 5b).
Pathogenicity of individual VACVs
The pathogenicity of individual VACVs was already evalu-
ated in female nude mice bearing human GI-101A xeno-
grafts (Zhang et al. 2007). The current study examined
whether the individual VACVs showed diVerential patho-
genicity in male mice after a single intravenous injection of
1 £ 107 pfu of virus, and whether an intact immune system
could overcome the infections of VACVs. In C6 glioma-
bearing nude male mice, wt-WR was extremely virulent
(Fig. 5c). Mice exhibited over 30% body weight loss by
day 7 after virus injection, and all mice died by day 11.
Pocks on the tail and footpad and swelling of the mouth
region were observed. Male mice injected with the TK¡
WR strain lost 22% of their body weight by the end of the
14 days, similar to mice injected with wt-LIVP strain. In
contrast, no signiWcant weight loss was observed in mice
injected with GLV-1h68 or other recombinant viruses. The
immunocompetent C57BL/6 mice, bearing B16-F10 mela-
noma on foot pad, showed a greater tolerance to viral path-
ogenicity (Fig. 5c). All mice injected with the wt-WR strain
survived for the duration of the study; however, on average
over 10% of body weight was lost by day 10. Male mice
injected with the TK¡ WR or the LIVP strains showed little
weight loss, suggesting that a competent T-cell system
plays an important role in Wghting against virus infection.
Tissue distribution of individual VACVs
We next looked at virus localization in individual tis-
sues. Table 2 summarizes the virus distribution data in
C6 tumor-bearing nude male mice after intravenous
injection of individual virus strains. In this experiment,
mouse organs were collected 14 days after virus injec-
tion. However, mice injected with wt-WR were sacri-
Wced and analyzed on day 7 due to extreme toxicity. As
shown in Table 2, the wt-WR injection resulted in a
broader distribution of the virus in healthy mouse tis-
sues, including an alarmingly high titer in the brain. The
inactivation of the TK gene led to signiWcant reductions
in the viral titers in mice injected with the TK¡ WR
strain; however, viral titers of up to 106 pfu per gram
of tissue were still present in the brain tissues. The
wt-LIVP, on the other hand, showed a markedly diVerent
distribution pattern. No viral particles were recovered
from the brain tissues in three of the four tumor-bearing
mice. Mice injected with GLV-1h68 had no virus recov-
ery from brain, testis, or bladder tissues, and very low
levels of viral particles recovered from kidney, liver, or
heart tissues in only one of the four mice. Viral particles
were also recovered from the spleen tissues in two of the
mice. Lung tissues seemed to be relatively susceptible to
the GLV-1h68 infection, with up to 103 pfu of the virus
per gram of tissue found in three mice. The implanted
C6 glioma tumors, however, were colonized heavily
with either WR or LIVP strains. The greatly reduced bio-
distribution of GLV-1h68 in various mouse organs was
in agreement with the viral replication data in mouse primary
cells (MEFs in Fig. 5b).
In melanoma-bearing immunocompetent mice, no virus
particles were recovered from non-tumor tissues 10 days
after the virus injection (Table 2), even for mice injected
with wt WR, suggesting the importance of T cells in the
Wght against viral infection. The viral titers were also lower
in the tumor tissues, in parallel with the in vitro replication
data (Fig. 5b).
Fig. 4 GLV-1h68 showed a unique genetic makeup that was distinct
from its parental LIVP strain. Genes outlined by navy blue have corre-
sponding paralogs in the left terminus. Genes in light blue are unique
for WR strain, and those in light orange are unique for GLV-1h68. The
orthologous genes are linked by dashed lines. GL277 (encoding inter-
leukin-18-binding protein) in GLV-1h68 had an ortholog WR013 in the
left terminus of WR genome. The majority of the wt-LIVP population
had sequences in the CrmE (mO259R) and v-GAAP (mO261R) gene
segments that are similar to other Lister strains426 Mol Genet Genomics (2009) 282:417–435
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The contribution of F14.5L inactivation
Given the promising data on GLV-1h68 from infection
studies and genome comparisons, direct experimental tests
probed next the pathogenicity eVect of individual genes.
Unlike the well known TK or HA gene in the VACV
genome, the F14.5L is relatively new and less studied. We
therefore focused our direct experimental tests on whether
the insertion of an expression cassette in the F14.5L con-
tributed to the attenuation of GLV-1h68. We constructed an
F14.5L-revertant virus GLV-1e135, in which the F14.5L
was restored to its wild-type LIVP sequence (Fig. 6a). To
Fig. 5 Replication and pathoge-
nicity of diVerent VACV strains. 
a Genetic constructs for diVerent 
VACV strains (reproduced from 
Zhang et al. 2007). A single base 
substitution created a premature 
stop codon; therefore, the TK 
gene in LIVP wt or GLV-1d27 
was naturally inactivated. pSEL, 
VACV synthetic early late pro-
moter; p7.5 and p11K, VACV 
7.5 early/late and 11k promoters; 
TFR, human transferrin recep-
tor. b The replication of diVerent 
VACV strains was studied in 
various cell cultures. c The path-
ogenicity was evaluated by 
change in body weight after a 
single, intravenous injection of 
each individual virus at 107 pfu 
per mouse, in nude mice bearing 
C6 glioma, and C57BL/6 mice 
bearing B16-F10 melanoma. 
Change of body weight (%) was 
calculated as follows: 
[(b ¡ t) ¡ (b ¡ t)] £ 100/
(b ¡ t), where b and t are the 
body weight and tumor weight 
(estimated by tumor size; 
1c m 3 = 1 g) on the day of virus 
injection, and b and t are the 
corresponding weights on the 
day of monitoring. The average 
weight change for each group is 
presentedMol Genet Genomics (2009) 282:417–435 427
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diVerentiate the contribution of the inactivation of F14.5L
by itself from the contribution by the RUC-GFP expression,
GLV-1h71, an F14.5L-null virus, was used as a control in
which a short nonsense sequence was inserted into the
F14.5L locus to interrupt the F14.5L gene (Fig. 6a). GLV-
1e135 was Wrst studied in CV-1 cells, and its infection and/
or replication capacities were compared to GLV-1h68 or
GLV-1h71. There appeared to be an increase in virus infec-
tion and/or replication for GLV-1e135 and GLV-1h71
compared to GLV-1h68 (Fig. 6b). At 24 h after the infec-
tion, the viral titer recovered from the infected CV-1 cells
was the highest for GLV-1e135 (6.9 £ 106 pfu/106 cells,
p < 0.001 vs. GLV-1h71 or GLV-1h68), followed by GLV-
1h71 (2.5 £ 106 pfu/106 cells), which was also signiWcantly
(p = 0.002) higher than that of GLV-1h68 (1.0 £ 106 pfu/
106 cells).
To study the virulence of the F14.5L-revertant and
F14.5L-null viruses, nude female mice were administrated
intranasally with 2 £ 106 pfu/20 l of the individual
viruses, including GLV-1h68, GLV-1e135, and GLV-1h71.
The mice were monitored twice weekly for body weight,
and the survival rate was recorded for each treatment group
for a period of 10 weeks (Fig. 6c, d). Two of the mice
treated with GLV-1h68 died during this study. The diVer-
ence between the PBS treated group and the GLV-1h68-
treated group was not signiWcant (p = 0.143, log rank test).
Two more mice died in the GLV-1h71-treated group.
However, the survival rate for the GLV-1h71 group was
not signiWcantly diVerent from that of the GLV-1h68 group
(p = 0.361). In contrast, all mice in the GLV-1e135-treated
group died during the study. This was a statistically sig-
niWcant diVerence from the GLV-1h68 treated group
(p = 0.0069), even though the diVerence was not signiWcant
when compared to the GLV-1h71 group (p = 0.068).
In contrast to a typical acute toxicity study, the applica-
tion dosage in this study was purposely kept low so that the
subtle diVerences between recombinant viruses became
obvious over the time. All mice died during the study had
lost noticeable amounts of weight before their deaths
(Fig. 6d). When the body weight for those surviving mice
was compared at the end of the study, the ANOVA showed
an overall signiWcance of 0.001. The mean body weight in
the GLV-1h71-treated mice was 21.6 g, which was signiW-
cantly lower than that of the GLV-1h68-treated group
(mean = 24.6 g,  p = 0.004) or the PBS control mice
(mean = 25.5 g, p < 0.001). The virulence of these recom-
binant viruses seemed to correlate well with their titers in
the CV-1 cells 24 h after virus infections (Fig. 6b).
Discussion
In this study, we compared the pathogenicity, tissue tro-
pism, and genomic features of the highly attenuated
Table 2 Distribution of VACV in healthy tissues versus tumors
Mean § standard deviation of viral pfu/g of tissues 14 days after infection with 107 pfu of virus injected via tail vein (n =4 )
a Mice were sacriWced on day 7 after virus injection
b wt-LIVP or GLV-1d27 was naturally TK¡
c pfu/20 l of serum
d Mice were sacriWced on day 10 after virus injection
e No virus was recovered from all tissues tested
wt-WRa TK¡ WR wt-LIVPb GLV-1d27b GLV-1f65 GLV-1h68
Nude male mice bearing C6 glioma
Brain 1.4 § 1.0 £ 107 1.9 § 2.7 £ 106 1.2 § 2.5 £ 103 8.4 § 8.3 £ 102 00
Kidneys 5.3 § 10.7 £ 106 7.9 § 10.1 £ 102 6.1 § 11.4 £ 102 3.5 § 6.9 £ 101 3.3 § 6.7 £ 101 3.7 § 7.3 £ 101
Lungs 1.9 § 2.6 £ 106 2.1 § 2.4 £ 103 3.0 § 3.2 £ 103 1.4 § 2.0 £ 104 6.8 § 13.4 £ 103 2.4 § 4.5 £ 103
Spleen 1.6 § 1.0 £ 106 1.8 § 0.9 £ 103 1.9 § 3.4 £ 102 1.0 § 0.7 £ 103 1.0 § 2.1 £ 102 1.7 § 2.5 £ 102
Testes 9.8 § 15.3 £ 104 1.7 § 0.1 £ 103 5.9 § 7.3 £ 104 7.5 § 15.1 £ 102 00
Bladder 2.8 § 4.6 £ 105 1.2 § 2.1 £ 103 6.4 § 7.8 £ 103 2.9 § 5.9 £ 102 00
Liver 7.1 § 4.5 £ 103 5.6 § 9.8 £ 103 3.4 § 4.5 £ 104 3.4 § 6.7 £ 101 9.7 § 12.4 £ 101 3.1 § 6.2 £ 101
Heart 1.4 § 1.9 £ 105 06 . 0 § 12.7 £ 103 006 . 3 § 12.6 £ 101
Serumc 6.0 § 2.7 £ 102 00000
Tumor 1.8 § 1.5 £ 108 3.7 § 2.6 £ 107 5.4 § 2.9 £ 107 2.9 § 1.6 £ 107 3.9 § 3.5 £ 107 1.9 § 1.6 £ 107
C57BL/6 male mice bearing B16-F10 melanomad
Tissuese 000000
Tumor 9.9 § 11.6 £ 106 2.2 § 1.4 £ 106 5.4 § 4.3 £ 106 9.5 § 7.9 £ 105 2.5 § 1.8 £ 105 2.3 § 0.2 £ 105428 Mol Genet Genomics (2009) 282:417–435
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recombinant GLV-1h68 with WR, COP and related viridae.
The in vivo studies show the reduced pathogenicity
phenotype of GLV-1h68, previously conWrmed in female
nude mice bearing GI-101A breast tumor xenografts
(Zhang et al. 2007), and now in male nude mice bearing
C6 glioma and a melanoma model in immunocompetent
mice. The comparative genome sequence analysis oVered
detailed functions of all infection-involved individual
genes, and showed the uniqueness of GLV-1h68 and its
evolutionary relationship. These Wndings provided a foun-
dation for further studies on the eVects of individual genes
and gene variants. Detailed experimental examination of
the eVects of individual ORFs is time-consuming and will
require a number of separate studies. Our study here
focused on the eVects of individual disruptions and
inserted cassettes in the F14.5L, J2R and A56R loci of
GLV-1h68 that resulted in reduced pathogenicity in mice.
This is the Wrst study attempting to diVerentiate the contri-
bution of an inactivated viral gene (e.g. F14.5L) from that
of an expression cassette (in the F14.5L locus) on the
attenuation of a VACV (e.g. GLV-1h68). In the following
discussion, we present the combined insights from both
Fig. 6 Contribution of an 
expression cassette in the 
F14.5L locus on the attenuation 
of GLV-1h68. a The schematic 
presentation of the F14.5L-null 
and revertant viruses derived 
from GLV-1h68. b The replica-
tion of the F14.5L-null and 
revertant viruses was studied in 
CV-1 cells, and compared to that 
of GLV-1h68. The virulence of 
the F14.5L-null and revertant 
viruses was investigated in nude 
mice by an intranasal application 
of 2 £ 106 pfu of individual 
virus per mouse. The survival 
and body weight of the mice 
were monitored for 10 weeks 
and presented in c and dMol Genet Genomics (2009) 282:417–435 429
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the bioinformatics and the experimental approaches applied
in this study.
Comparison choice regarding diVerent vaccinia strains
Some of the vvDD strains and the Wyeth TK-strains have
been used as oncolytic strains under clinical investiga-
tion. They would be ideal candidates for comparison with
GLV-1h68, which is now also as GL-ONC-1 undergoing
a Phase I/II trial. Unfortunately, the genome sequence for
any of these strains is not available or publicly accessi-
ble. The vvDD strains were derived from the WR strain,
with the double deletion of VGF and TK. However, it is
not safe to assume that a vvDD strain would have a simi-
lar genomic sequence as that of wt WR, given the fact
that GLV-1h68, derived from an isolate from LIVP,
showed a unique genetic make up very diVerent from
LIVP. Therefore, we chose to use the WR wt, which has a
complete genome sequence for analyzing, and a WR
TK¡ strain, since we know that LIVP (wt) was a TK¡
strain, as the best available strains for comparison. On top
of that, the WR strain has been the most widely studied
strain in laboratories all over the world. We would gain
more insight from the comparison with these laboratory
WR strains.
Even though we did not directly compare our strains
with the vvDD strains or the Wyeth TK¡ strains, from pub-
lished data, we can get a general idea what could be pre-
dicted from a direct comparison. During the construction of
a vvDD strain, two copies of the viral VGF genes were Wrst
inactivated by the insertion of the lacZ gene under the con-
trol of the p11 promoter, and the resulting mutant vSC20
(Buller et al. 1988) was used as the parental virus for the
double deletion mutant vvDD, in which the TK gene was
also inactivated by the insertion of one or more foreign
gene expression cassettes. In one of the vvDD strains,
vvDD-GFP (McCart et al. 2001), the EGFP gene under the
control of a synthetic early-late promoter, and the gpt gene
under the control of the p7.5 promoter were inserted in the
TK locus. In nude mice injected with 107 pfu of vvDD-
GFP, the median viral recovery from ovary tissues was as
high as 8.6 £ 106 pfu/mg total protein 8 days after the
infection, suggesting that neither VGF nor TK was respon-
sible for gonadotropism in female mice. However, both
VGF¡ and TK¡ contributed to reduced viral replication in
mouse brain. If we would like to Wnd out which gene(s)
contribute to gonadotropism in female mice, a genomic
comparison with GLV-1h68 would help to narrow down
the selection of the candidates. Of course, considerable
amount of studies are required to pinpoint the exact
gene(s). We hope that with this work including the detailed
triple genome comparison, the combined eVorts from our
scientiWc community would speed up the discovery
process, and eventually, an optimized oncolytic virus with
maximum oncolytic activity yet minimum pathogenicity
will become available to beneWt cancer patients.
ORFs involved in host-range selection
Many diVerences in ORFs among the GLV-1h68, WR and
COP strains can be attributed to the ORFs encoding anky-
rin-like proteins (Table 1). Because these proteins control
the interactions between the integral membrane proteins
and the elements of the cell cytoskeleton, the proteins
could be involved in functions related to transcriptional
initiation, cell cycle regulation, cytoskeleton formation,
ion transport and signal transduction (Lux et al. 1990;
Mosavi et al. 2004). It has been proposed that diVerent sets
of the ankyrin-like proteins encoded by VACVs, as well as
the level of their synthesis, allow for the Wne regulation of
virus replication and the determination of tissue tropism in
infected animals (Shchelkunov et al. 1993). Recent studies
on the M-T5 host-range protein of myxoma virus, which
contains multiple ankyrin repeats, illustrate that interac-
tions of M-T5 with Akt and cullin-1 (both components of
host cell signaling networks) can have a profound impact
on poxvirus tropism (Johnston et al. 2005; Wang et al.
2006).
It has been described that the deletion of two vaccinia
host-range genes (K1L and C7L) greatly reduces the ability
of VACV to replicate in a variety of human cell lines
(Gillard et al. 1986). Restoration of the K1L gene in the MVA
genome, however, failed to release the virus from its host
restriction on monkey or human cells (Perkus et al. 1990),
suggesting that there are other host-range determination
genes yet to be recognized. K1L and C7L seemed to be well
conserved among GLV-1h68, WR and COP. Yet, we found
that, while GLV-1h68, along with the other two recombi-
nant viruses, infected and replicated in human, monkey and
rat cells, it did not replicate in mouse embryonic Wbroblasts
(MEFs) (Zhang et al. 2007; Fig. 5b). In contrast, wt-LIVP
did replicate in MEFs, giving a virus yield of just 10-fold
less than wt-WR (Fig. 5b). It is reasonable to speculate that
the restricted replication of these three recombinant viruses
in MEFs was caused by the inactivation of the F14.5L
locus. Our unpublished data, however, suggest that the dis-
rupted F14.5L was not responsible for this restricted repli-
cation. We have observed that a virus isolate derived from
GLV-1h68, which had a restored F14.5L, failed to replicate
in the MEFs as well (data not shown). Now we know that
wt-LIVP was a mixed population, and that GLV-1h68 was
derived from a unique isolate from this mixed population,
a genome sequencing and comparative analysis with an
LIVP isolate capable of replicating in MEFs would help to
identify genes responsible for the restricted replication of
GLV-1h68 in primary mouse cells.430 Mol Genet Genomics (2009) 282:417–435
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ORFs involved in host immune modulation
B28R and A53R, encoding two vTNFR proteins, are equiv-
alent to Cowpox virus (CPV) genes cytokine response
modiWer B (crmB) and crmC, respectively. However, both
B28R and A53R are fragmented and found to be inactive in
most VACV strains, including WR and COP (Alcami et al.
1999). Nevertheless, GLV-1h68 was found to carry an
intact A53R gene (GL241), which encoded a secreted TNF-
receptor-like protein of 186aa that was the same length
as CPV crmC (Fig. 7). CrmC was also found intact in
the Lister isolate VACV107 (GenBank accession no.
DQ121394). As a soluble vTNFR that interferes with host
immune functions, A53R in GLV-1h68 could be a potential
candidate for disruption, in order to further attenuate the
virus.
Unlike USSR, Evans and other Lister derivatives,
GLV-1h68 did not have a crmE-like sequence in the
genome. USSR recombinants lacking crmE were found to
be attenuated, while the expression of an inserted crmE
gene in the genome of WR resulted in enhanced virulence
(Reading et al. 2002). The crmE deWciency in GLV-1d27
or GLV-1h68, therefore, may have contributed to a
greater attenuation in comparison to wt-LIVP (the major-
ity of wt-LIVP was crmE positive). VACV strains Lister,
USSR and Evans also express the v-GAAP protein. The
deletion of this gene from VACV does not aVect virus
replication in cell cultures, but signiWcantly alters virus
virulence in murine infection models (Gubser et al. 2007).
GLV-1h68 does not have a v-GAAP gene. This gene
would therefore be a good candidate to be inserted into
the genome of GLV-1h68 to bring additional attenuation
to the virus.
It has been shown that deletion of the CPV 38 K gene
encoding the well-known orthopoxvirus serpin (also known
as SPI-2 or CrmA) in either the cowpox or rabbitpox virus
genome resulted in attenuation in murine intranasal models
(Thompson et al. 1993). The deletion mutants from the WR
strain that lack the SPI-2 or SPI-1 coding sequence display
similar in vitro replication proWles and in vivo virulence as
wt-WR and the revertant viruses (Kettle et al. 1995). How-
ever, the derivative of the WR strain with both SPI-1 and
SPI-2 deleted has been shown to be signiWcantly attenuated
and less pathogenic to mice (Guo et al. 2005). The incon-
clusive Wndings on SPI-1 and SPI-2 may have resulted from
the diVerence in the way the “deletion” mutants are con-
structed (more details in later discussion). Nevertheless, if
inactivation of the SPI-2 gene indeed reduces virulence of
the virus, the fragmented SPI-2 gene in GLV-1h68 (GL266
and GL267) may have contributed to its attenuation. Fur-
thermore, the lack of a functional SPI-2 gene product may
enhance the immunogenicity of the virus (Zhou et al.
1990).
It has been observed that A39R induces robust responses
in human monocytes, including cell aggregation, induction
of proinXammatory cytokines, and upregulation of the
monocyte cell surface marker ICAM-1. All of these eVects
suggest that A39R inXuences the immune responses of vac-
cinia-infected hosts (Comeau et al. 1998). The A39R pro-
tein is found to be expressed by VACV strains COP, Evans,
Lister, and USSR, but not WR. Expression of an inserted
COP A39R gene in the WR strain was found to be associ-
ated with an increase in inWltration and oedema formation,
suggesting that the A39R protein has pro-inXammatory
properties (Gardner et al. 2001). The fact that A39R was
intact in LIVP and in GLV-1h68, but truncated in WR,
Fig. 7 Sequence alignment of crmC gene for selected poxvirus
strains. The ORFs for CrmC in selected poxvirus strains were trans-
lated into amino acids and their sequences were aligned using Clu-
stalX. GLV-1h68 exhibits an intact crmC gene (GL241), which is
highly identical to List172 in Lister isolate VACV107, and A56 gene
in Cowpox virus, all of which contain a typical signal peptide sequence
predicted by SignalP 3 software. Lister strain LC16mO seems to have
a full length protein, but its N-terminal sequence suggests that this pro-
tein is not secreted. The crmC genes in VACV strains Copenhagen and
WR are truncatedMol Genet Genomics (2009) 282:417–435 431
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suggests diVerences in immunogenicity, but requires further
experimental conWrmation.
Genome evolution of GLV-1h68
Our data also suggested a unique infection and replication
proWle of GLV-1h68 that was distinctively diVerent from
its parental strain LIVP. This distinction was particularly
evident in mouse primary cells, which warranted a closer
look at its genome evolution. A comparison of the sequence
of the major PCR product on the right terminal region of
wt-LIVP with GLV-1h68 supports our hypothesis that
GLV-1h68 was a unique isolate that diVered from the
majority of the wt-LIVP population (Figs. 3, 4). GLV-1h68
showed a unique genetic makeup which shared genes simi-
lar to those of WR strains.
These changes illustrated that the parental strain of
GLV-1h68 probably underwent two major rearrangement
events. First, there was perhaps a genetic exchange with a
WR-like VACV strain regarding the right terminal region.
The C-terminal of GL273 was most likely the site of the
recombination segment, since it was highly homologous to
WR199. GL274, GL275 and GL276 were also acquired dur-
ing the same genetic exchange, as they were similar to the
downstream  WR200, WR202 and WR201 genes, respec-
tively. A second major rearrangement occurred when the
parental strain lost part of its newly acquired WR-like
sequences at the region, and a copy of its left terminal
sequence, GL001 to GL015 genes, was duplicated, and then
appeared in its right terminal region. This exchange proba-
bly occurred in a laboratory where WR strains and the
parental strains of GLV-1h68 were used at the same time.
The sequence of the major PCR product on the right termi-
nal region of GLV-1d27 or GLV-1f65 was not determined,
but it is very likely to be similar, if not identical, to that of
GLV-1h68, given the fact that the same size PCR product
was obtained, and the history of stepwise virus construction
and puriWcation.
The contribution of F14.5L inactivation
F14.5L, reported as WR053.5 in WR, encodes a protein of
49 amino acids with a secretory signal peptide. This ORF
was very well conserved across diVerent VACV strains, as
well as in other poxviruses. There is a NotI restriction site
in the middle of F14.5L sequence, which was used to insert
a RUC-GFP expression cassette to create the recombinant
virus GLV-1d27, and subsequently the double-mutant virus
GLV-1f65, and the triple-mutant GLV-1h68 (Timiryasova
et al.  2000; Zhang et al. 2007). Our studies with the
F14.5L-revertant and the F14.5L-null viruses suggest that
the F14.5L locus in viral genome can be disrupted as a way
to attenuate VACV. The eVect of inactivation of F14.5L
locus by itself was not very substantial, but it would likely
become statistically signiWcant with a larger sample size.
The expression of an exogenous gene in the F14.5L locus
puts extra transcriptional and translational burden on the
virus and, together with the inactivation of F14.5L, resulted
in a signiWcantly attenuated virus: GLV-1h68. It is possible
that the expressed GFP could be toxic to some host cells
that would inhibit viral replication. However, our unpub-
lished data suggest that other foreign genes expressed in the
same locus also attenuated the virus to similar extent; there-
fore the reduced virulence was not likely due to the toxicity
brought by GFP. In a recent publication, WR53.5 is found
to be an envelope protein of an intracellular mature virus
that mediates cell adhesion (Izmailyan and Chang 2008). In
that study, the WR53.5-deletion mutant virus, which con-
tains a gpt expression cassette in the WR53.5 locus, exhibits
reduced virulence in mice. It is conceivable that the expres-
sion of gpt, in addition to the inactivation of WR53.5L, may
have contributed to the reduced virulence.
The contribution of J2R inactivation
The TK negative phenotype was conWrmed for the wild
type LIVP population. A TK¡ virus requires TTP for DNA
synthesis, leading to a preferential viral replication in divid-
ing cells and ultimately enhanced tumor speciWcity and
minimal infection of neighbor tissues. The TK¡ phenotype
may explain, at least in part, why the wt-LIVP strain
appeared to be less virulent than wt-WR in animal studies
(Fig. 5c; Table 2); however, it cannot explain the observed
diVerences in neurovirulence and gonadotropism between
L I V P  a n d  W R  s t r a i n s .  W e  s a w  e a r l i e r  i n  f e m a l e  n u d e
tumor-bearing mice that, even as disruption of the TK gene
in the WR genome contributed signiWcantly to reduced
viral entry or replication in brain tissues (a 3-log reduction),
merely a 2.5-fold reduction was observed in ovary tissues
(Zhang et al. 2007). In this study, the disruption of the TK
gene in the WR genome resulted in on average a 7-fold and
a 58-fold reduction in viral titers in the brain and testis tis-
sues, respectively (Table 2). We therefore conclude that,
while a TK¡ phenotype in the WR strain signiWcantly
reduced its neurovirulence (more evident in female mice)
and reduced gonadotropism in male mice, it had little eVect
on gonadotropism in female mice. In contrast, despite the
fact that the brain and ovary tissue were found to be free of
viral particles in mice treated with either wt-LIVP or GLV-
1h68 (both were TK¡) (Zhang et al. 2007), the wt-LIVP did
show a similar viral titer in testes as the WR strains in this
new study (Table 2). We suspect that gene(s) other than the
TK¡ phenotype contributed to the absence of gonadotro-
pism in mice observed for the three recombinant viruses
derived from LIVP, including GLV-1h68. However, it was
not clear how much a TK¡ phenotype in the LIVP strains432 Mol Genet Genomics (2009) 282:417–435
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might have contributed to the absence or reduced neurovi-
rulence and gonadotropism in mice.
It was also shown that the distribution of GLV-1f65 was
further reduced in the normal tissues when compared to
those injected with GLV-1d27 (Table 2). Both viruses were
TK¡, and the only diVerence was that GLV-1f65 contained
a foreign gene expression cassette in its J2R locus. Similar
to the foreign gene (RUC-GFP) expression in the F14.5L
locus that contributed to the attenuation of GLV-1h68, the
expression of lacZ in the J2R locus may have further con-
tributed to the attenuation of GLV-1f65, and the attenuation
of GLV-1h68. In the survival study reported previously
(Zhang et al. 2007) the mice injected with GLV-1f65 did
outlive the ones injected with GLV-1d27.
The contribution of A56R inactivation
The A56R gene, which encodes hemagglutinin, is another
nonessential gene that can be inactivated to obtain a more
attenuated virus. It has been observed that inactivation of
the HA gene leads to greater attenuation of WR than of
LC16mO (a temperature-sensitive and lower neuroviru-
lence strain isolated from the Lister LO strain) and to no
apparent attenuation of LO-1 (an isolate of Lister Elstree
strain) (Shida et al. 1988). In our studies, disruption of the
HA gene by the insertion of an expression cassette further
attenuated the virus (Zhang et al. 2007). While mice
injected with GLV-1f65 (F14.5L¡ and TK¡) lived up to
116 days after virus injection, all of the mice injected with
GLV-1h68 (F14.5L¡, TK¡ and HA¡) survived for the dura-
tion of study (130 days post virus infection). Further studies
are needed to investigate how much of the attenuation in
GLV-1h68 could be attributed to the inactivation of HA
itself, and how much was contributed by the expression of a
foreign gene (gusA) in the A56R locus.
The contribution of foreign gene expression
GFP expression could be toxic to the host cells and may
have reduced the replication of GLV-1h68, thus the GFP
would be the cause of the reduced pathogenicity. Data pub-
lished before (Zhang et al. 2007) and here suggest that the
expression of -galactosidase in the TK locus attenuated
the virus as well. We are currently conducting a whole set
of studies in which the strength of diVerent viral promoters,
the size of the transgenes, the 2nd structure of the tran-
scripts, and the locus of the insertions are the factors under
investigation. Our preliminary data suggest that the obser-
vation that transgene expression appears to reduce viral
replication is generally true. All these data, when they
become available, will be presented in a new study.
A review of published data so far by other investigators
also suggests that the expression of inserted foreign gene(s)
may play a role in reduced virulence observed with those
engineered viruses. For example, when the SPI-1 or SPI-2
gene was simply deleted, no reduced virulence was
observed (Kettle et al. 1995). But when both SPI-1 and
SPI-2 genes were inactivated by the insertion of a func-
tional gpt expression cassette and an Escherichia coli lacZ
gene expression cassette, respectively, the resulting mutant
was markedly attenuated (Guo et al. 2005). It is possible
that the eVect of individual gene deletion was not signiW-
cant, but the inactivation of both genes made the attenua-
tion more evident. The way the double-mutant virus was
constructed, however, has made us wonder how much of
the attenuation was actually contributed by the expression
of transgenes.
General considerations and conclusions
We investigated the genetic diVerences between GLV-1h68
and related VACVs. A Wrst comprehensive analysis includ-
ing function predictions for all found genome diVerences is
easily gained by bioinformatics and comparative genome
analysis, even though this method cannot detect and rule
out further diVerences on smaller polymorphisms (e.g.
SNPs). Such more subtle eVects and diVerences require
extensive genetic and molecular studies to test individual
genes in a number of strains and their direct eVects in diVer-
ent infection scenarios. Table 3 summarizes a number of
genome diVerences, as examined and discussed here. It is
important to realize that the functions of viral genes could
be strain-speciWc, tissue-speciWc, or host-speciWc. The viru-
lence genes, which are important for one VACV strain,
may play a minimal role in the virulence for another VACV
strain. The inactivation of a certain viral gene may inXu-
ence the replication of VACV in one tissue type but not
other tissues in the same host, or may reduce the pathoge-
nicity of the virus to one host species but not to others.
There might also be synergistic eVects involving multiple
viral genes. In this report, we focused our analysis on the
diVerences between the viral genes that were absent or frag-
mented in certain strains and the corresponding viral genes
in the Lister, WR and COP strains. Using sequences avail-
able from additional VACV genomes, in combination with
functional transcription and proteome analysis, it is possi-
ble to rationally design more optimized oncolytic virus
strains to beneWt cancer therapy in human patients. The
analysis of GLV-1h68 is an important step towards this
goal, as demonstrated here by direct sequence data, func-
tional tests and tissue tropism.
This study also suggests that insertion of a foreign
gene expression cassette in a nonessential locus in the
viral genome is a practical way to attenuate VACVs,
especially if the nonessential locus itself contains a
virulence gene. The challenge will then be to reduce theMol Genet Genomics (2009) 282:417–435 433
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virulence of the virus without compromising too much
on the replication competency of the virus, the key to its
oncolytic activity.
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